A cost analysis on the pattern of asthma prescribing in the UK

There is a need to establish the proportion of adult asthmatics at each step of the recommended asthma management guidelines, the cost of their prescribed treatment, and a revised cost of treatment assuming patients who were suboptimally controlled were moved up a step. Actual prescription and cost figures and a theoretical projection of an ideal scenario was calculated from a sample of general practices in Great Britain from the Doctors Independent Network. They comprised 102 nationally distributed practices and 17,206 adult patients with a diagnosis of, and prescription related to, asthma recorded between October 1993 and March 1994. Ninety-one per cent of patients received treatment within a recognized step of the guidelines. Of these, 80% were at steps 1 and 2. Employing excess inhaled beta-agonist use as a proxy for control of asthma, between 55% and 69% of patients at Steps 1-3 should receive treatment at a higher step. This could lead to an increased expenditure of up to Pound Sterling 4.66 per adult patient per month. This would imply a rise in the annual UK cost of antiasthma prescriptions for adults from Pound Sterling 388m to a possible Pound Sterling 533m. The United Kingdom Government audit commission has suggested that current expenditure on asthma treatment appears to be insufficient. Using an entirely different approach this study has confirmed that a significant increase in asthma prescribing costs is likely to be needed if optimal control of asthma is to be achieved.

This article has been cited by other articles:

				M. Moffat, J. Cleland, T. van der Molen, and D. Price Poor communication may impair optimal asthma care: a qualitative study Fam. Pract., February 1, 2007; 24(1): 65 - 70. [Abstract] [Full Text] [PDF]

				A. E. Williams, A. C. Lloyd, L. Watson, and K. F. Rabe Cost of scheduled and unscheduled asthma management in seven European Union countries Eur. Respir. Rev., June 1, 2006; 15(98): 4 - 9. [Abstract] [Full Text] [PDF]

				D. Vervloet, A. E. Williams, A. Lloyd, and T. J. H. Clark Costs of managing asthma as defined by a derived Asthma Control TestTM score in seven European countries Eur. Respir. Rev., June 1, 2006; 15(98): 17 - 23. [Abstract] [Full Text] [PDF]

				R. H. Green, C. E. Brightling, S. McKenna, B. Hargadon, N. Neale, D. Parker, C. Ruse, I. P. Hall, and I. D. Pavord Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Eur. Respir. J., June 1, 2006; 27(6): 1144 - 1151. [Abstract] [Full Text] [PDF]

				R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]

				J Wright, D Brocklebank, and F Ram Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD) Qual. Saf. Health Care, January 12, 2002; 11(4): 376 - 382. [Abstract] [Full Text] [PDF]

				F. S F Ram, J. Wright, D. Brocklebank, and J. E S White Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta 2 agonists bronchodilators in asthma BMJ, October 20, 2001; 323(7318): 901 - 901. [Abstract] [Full Text]